{"id":"valsartant-treatment","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"2-3","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"1-2","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in reduced blood pressure and improved cardiac function.","oneSentence":"Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:29.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT00409487","phase":"PHASE4","title":"Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2006-12","conditions":"Hypertension,, Obstructive Sleep Apnea","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6125559,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valsartant treatment","genericName":"Valsartant treatment","companyName":"University Hospital, Grenoble","companyId":"university-hospital-grenoble","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}